Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

Distler, Oliver, Highland, Kristin B., Gahlemann, Martina, Azuma, Arata, Fischer, Aryeh, Mayes, Maureen D., Raghu, Ganesh, Sauter, Wiebke, Girard, Mannaig, Alves, Margarida, Clerisme-Beaty, Emmanuelle, Stowasser, Susanne, Tetzlaff, Kay, Kuwana, Masataka, Maher, Toby M.·2019·New England Journal of Medicine
DOI 10.1056/nejmoa1903076

Cited by (1,000)

Items 801–900 of 1,000

  1. Efficacy and safety of antifibrotic drugs for interstitial lung diseases other than IPF: A systematic review, meta-analysis and trial sequential analysis
    Mei Yang, Yuying Tan, Ting Yang, Dan Xu, Mei Chen, Lei Chen · 2025 · PLoS ONE
  2. Systemic pharmacotherapy approaches for the treatment of systemic sclerosis
    Stefano Di Donato, Zsuzsanna Hortobagyi McMahan, Michael Hughes · 2025 · Expert Opinion on Pharmacotherapy
  3. The role of antifibrotic therapies in the treatment of systemic sclerosis–associated interstitial lung disease
    Gonçalo Boleto, Jérôme Avouac, Yannick Allanore · 2022 · Therapeutic Advances in Musculoskeletal Disease
  4. Emerging Evidence and Treatment Perspectives from Randomized Clinical Trials in Systemic Sclerosis: Focus on Interstitial Lung Disease
    Caterina Oriana Aragona, Antonio Giovanni Versace, Carmelo Ioppolo, Daniela La Rosa, Rita Lauro, Maria Concetta Tringali, Simona Tomeo, Guido Ferlazzo, William Neal Roberts, Alessandra Bitto et al. · 2022 · Biomedicines
  5. Wertigkeit der CT und des transthorakalen Lungenultraschalls bei PatientInnen mit systemischer Sklerose
    Michael Grohs, Florentine Moazedi‐Fuerst, Holger Flick, Klaus Hackner, Andreas Haidmayer, Sabin Handzhiev, H. P. Kiener, Judith Löffler‐Ragg, G. Mathis, G. Mostbeck et al. · 2022 · Zeitschrift für Rheumatologie
  6. Emerging opportunities to treat idiopathic pulmonary fibrosis: Design, discovery, and optimizations of small-molecule drugs targeting fibrogenic pathways
    Wenxin Luo, Yilin Gu, Siyu Fu, Jiaxing Wang, Jifa Zhang, Yuxi Wang · 2023 · European Journal of Medicinal Chemistry
  7. Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis
    Dinesh Khanna, Frank Kramer, Josef Höfler, Mercedeh Ghadessi, Peter Sandner, Yannick Allanore, Christopher Paul Denton, Masataka Kuwana, Marco Matucci‐Cerinic, Janet Elizabeth Pope et al. · 2024 · Rheumatology
  8. Comparing the safety and efficacy of nintedanib starting dose in patients with connective tissue disease-associated interstitial lung diseases
    Masahiro Ayano, Kazuya Tsubouchi, Kunihiro Suzuki, Yasutaka Kimoto, Yojiro Arinobu, Koichi Akashi, Takahiko Horiuchi, Isamu Okamoto, Hiroaki Niiro · 2024 · Scandinavian Journal of Rheumatology
  9. Proteinase 3 (PR3)-antineutrophil cytoplasmic antibody (ANCA)-associated vasculitic neuropathy in diffuse cutaneous systemic sclerosis: a rare duo
    Yasser Radwan, Sarah E. Berini, Floranne C. Ernste, Ashima Makol · 2019 · BMJ Case Reports
  10. Progressive Fibrosing Interstitial Lung Disease. A Proposed Integrated Algorithm for Management
    Francesco Varone, Giacomo Sgalla, Bruno Iovene, Luca Richeldi · 2020 · Annals of the American Thoracic Society
  11. A new nucleosomic-based model to identify and diagnose SSc-ILD
    Julien Guiot, Monique A. Henket, Béatrice André, Mariëlle Herzog, Nathalie Hardat, Makon‐Sébastien Njock, Catherine Moermans, Michel Malaise, Renaud E. Louis · 2020 · Clinical Epigenetics
  12. Immunomodulation in Autoimmune Interstitial Lung Disease
    Benjamin Seeliger, Antje Prasse · 2020 · Respiration
  13. Systemic Sclerosis: Current State and Survival After Lung Transplantation
    Artem Minalyan, Lilit Gabrielyan, Shristi Khanal, Bikash Basyal, Chris T. Derk · 2021 · Cureus
  14. Increased Red Blood Cell Distribution Width in the First Year after Diagnosis Predicts Worsening of Systemic Sclerosis-Associated Interstitial Lung Disease at 5 Years: A Pilot Study
    Satoshi Ebata, Ayumi Yoshizaki, Takemichi Fukasawa, Asako Yoshizaki‐Ogawa, Yoshihide Asano, Kosuke Kashiwabara, Koji Oba, Shinichi Sato · 2021 · Diagnostics
  15. Thoracic lymphadenopathies in diffuse systemic sclerosis: an observational study on 48 patients using computed tomography
    Arthur Renaud, R. Pautre, Olivier Morla, Aurélie Achille, Cécile Durant, Olivier Espitia, Éric Frampas, C. Agard · 2022 · BMC Pulmonary Medicine
  16. Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial
    Takashi Ogura, Takafumi Suda, Naohiko Inase, Yasuhiko Nishioka, Arata Azuma, Masaki Okamoto, Ayako Takizawa, Tomohiro Ito, Klaus B. Rohr, Yoshikazu Inoue · 2022 · Respiratory Investigation
  17. Interstitial lung disease in patients with systemic sclerosis: what can we learn from the SENSCIS trial?
    Shervin Assassi, Sudhakar Tumuluri, Robert W. Levin · 2023 · Clinical and Experimental Rheumatology
  18. Management of systemic sclerosis‐associated interstitial lung disease in the current era
    Sogol Amjadi, David Roofeh, Rajaie A. Namas, Dinesh Khanna · 2020 · International Journal of Rheumatic Diseases
  19. Enfermedades pulmonares intersticiales. Una perspectiva actual
    MAURICIO SALINAS F, MATÍAS FLORENZANO V, Verónica Wolff C., Juan Carlos Rodrı́guez, Hugo Valenzuela C., C. Fernández García, Álvaro Undurraga · 2019 · Revista médica de Chile
  20. Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in Southern Taiwan: A Single-Center 10-Year Longitudinal Observation Cohort
    Chun‐Hsin Wu, Chun‐Yu Lin, Chih‐Hsin Hsu, Sheng‐Hsiang Lin, Chia‐Tse Weng · 2021 · Healthcare
  21. An IPF-like disease course in disorders other than IPF: how can this be anticipated, recognized, and managed?
    Athol Umfrey Wells, Vasileios Kouranos · 2021 · Expert Review of Clinical Immunology
  22. Chronic dyspnea with Raynaud's phenomenon and elevated ANA: A diagnosis of systemic sclerosis sine scleroderma
    Woon Hean Chong, Biplab Kumar Saha, Scott H. Beegle · 2022 · The American Journal of the Medical Sciences
  23. Patient-reported outcomes in systemic sclerosis: insights into quality of life and disease burden
    Alain Lescoat, Yen T. Chen, Dinesh Khanna · 2025 · Current Opinion in Rheumatology
  24. Targeting lactate metabolism to restore immune homeostasis: a precision therapeutic paradigm for rheumatoid arthritis
    Lin Zheng, A Xinyu, Shiyu Ma, Bo Xu, Zheng Xiang, Boran Cao, Jun Shen, Xirui Xu, Yiwei Cheng, Lei Ran et al. · 2025 · Frontiers in Immunology
  25. The importance of considering progression speed in systemic sclerosis—associated interstitial lung diseases: application of 2022 and 2024 clinical practice guidelines for progressive pulmonary fibrosis, a retrospective cohort study
    Anaïs Roeser, Pierre‐Yves Brillet, Stéphane Tran Ba, Frédéric A. Caux, Robin Dhôte, Hilario Nunès, Y. Uzunhan · 2025 · Respiratory Research
  26. Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis–Related Interstitial Lung Disease (Scleroderma Lung Study III ): An Investigator‐Initiated, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Trial
    Dinesh Khanna, Cathie Spino, Donald P. Tashkin, Elana J. Bernstein, Jonathan Gerald Goldin, Eric C. Kleerup, Airi Harui, Grace Ibrahim, Grace Hyun J. Kim, Suiyuan Huang et al. · 2025 · ACR Open Rheumatology
  27. Automated lung texture analysis for assessing interstitial lung disease in systemic sclerosis: Diagnostic accuracy in photon-counting-detector and conventional energy-integrating-detector CT
    Jasmin Happe, Cosimo Bruni, Lisa Jungblut, Nicholas Landini, Cecilia Strappa, Christian Blüthgen, Muriel Elhaï, Rucsandra Dobrota, Carina Mihai, Sinziana Muraru et al. · 2025 · European Journal of Radiology
  28. Benefits of nintedanib continuation in systemic autoimmune rheumatic disease-related progressive pulmonary fibrosis: KEIO-SARD-ILD-cohort
    Koji Suzuki, Mitsuhiro Akiyama, Kanako Shimanuki, Hiroyuki Fukui, Yuko Kaneko · 2025 · Seminars in Arthritis and Rheumatism
  29. Global, regional, and national burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2023, and projections to 2050: A systematic analysis for the Global Burden of Disease Study 2023
    Xiaoqian Ma, Lili Zhu, Huijuan Xiao, Yushan He, Huaping Dai · 2025 · Chinese Medical Journal - Pulmonary and Critical Care Medicine
  30. In Vivo Target Engagement Assessment of Nintedanib in a Double-Hit Bleomycin Lung Fibrosis Rat Model
    Vanessa Pitozzi, Paola Lorenza Caruso, Silvia Pontis, Barbara Pioselli, Francesca Ruscitti, Maria Gloria Pittelli, Costanza Anna Maria Lagrasta, Federico Quaini, Antonella Maria Nogara, Giancarlo Aquino et al. · 2025 · International Journal of Molecular Sciences
  31. Interstitial Lung Disease in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A European Multicenter Study
    Aglaia Chalkia, M. Kotnik, Timothy J Sadler, Spyridon Katechis, Rachel Jones, Ajay V. Kamath, Aladdin J Mohammad, Sara M. Monti, Chetan B. Mukhtyar, Viral Jayshinh Nanda et al. · 2026 · Arthritis & Rheumatology
  32. Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trial
    Anna‐Maria Hoffmann‐Vold, Shervin Assassi, Vincent Cottin, Michael Kreuter, Claudia Valenzuela, Marlies S Wijsenbeek, Hui Gu, Madhu Kanakapura, Ivana Ritter, Susanne Stowasser et al. · 2026 · Annals of the Rheumatic Diseases
  33. The diagnostic trajectories of Danish patients with autoimmune rheumatologic disease associated interstitial lung disease: an interview-based study
    Mette Brehm Johansen, Elisabeth M. Bendstrup, Jesper Rømhild Davidsen, Saher Burhan Shaker, HM Martin · 2023 · European Clinical Respiratory Journal
  34. Prognostic biomarkers of progressive pulmonary fibrosis in patients with interstitial lung diseases
    Н. А. Кузубова, Olga N. Titova, D.B. Sklyarova · 2023 · Meditsinskiy sovet = Medical Council
  35. Summary for Clinicians: Clinical Practice Guideline for the Treatment of Systemic Sclerosis–Associated Interstitial Lung Disease: Evidence-Based Recommendations
    Tanzib Hossain, Sydney B. Montesi, Elizabeth R. Volkmann, Carey Conley Thomson, Joseph K. Ruminjo, Richard M. Silver, Marya Ghazipura, Ganesh Raghu · 2023 · Annals of the American Thoracic Society
  36. Validation of a semi-quantitative method to assess interstitial lung disease severity and progression in systemic sclerosis by standard and low-dose HRCT scans
    Lucas Tschaler, Suzana Jordan, Trond Mogens Aaløkken, Mike Oliver Becker, Cathrine Brunborg, Cosimo Bruni, Christian Friedrich Clarenbach, Rucsandra Dobrota, Michael T. Durheim, Muriel Elhaï et al. · 2025 · RMD Open
  37. Lung Function Course of Patients With Pulmonary Fibrosis After Initiation of Anti‐Fibrotic Treatment: Real‐World Data From the Dutch National Registry
    Mark G. J. P. Platenburg, Gizal Nakshbandi, Catharina C. Moor, Aernoud A. van Batenburg, Rémy L.M. Mostard, Mareye Voortman, Linda A.A. Moonen, N Hekelaar, Maria J. Overbeek, Brigitte A.H.A. Bogaarts et al. · 2025 · Respirology
  38. Immunosuppressive Therapy for Usual Interstitial Pneumonia in Autoimmune Rheumatic Diseases: A Review
    Domenico Sambataro, Giulia Morina, Alessandro Libra, Stefano Palmucci, Francesco Pallotti, Giulio Geraci, Gaetano La Rocca, Francesco Ferro, Michele Moretti, Chiara Baldini et al. · 2025 · Medicina
  39. Updates in Diagnostic Tools for ILD
    Arsal Tharwani, Manuel L. Ribeiro Neto · 2025 · Journal of Clinical Medicine
  40. Connective tissue disease-associated interstitial lung disease: a rheumatologist's perspective
    A. Connerton, Eoghan M. McCarthy, Laura Durcan · 2025 · Breathe
  41. Pharmacological treatment of pulmonary fibrosis
    Won-Il Choi · 2020 · Journal of Korean Medical Association
  42. Interstitial Lung Disease Worsens Short- and Long-Term Outcomes of Systemic Rheumatic Disease Patients Admitted to the ICU: A Multicenter Study
    Lorrain Banuls, Juliette Vanoverschelde, Fanny Garnier, Matthieu Amalric, Samir Jaber, Jonathan Charbit, Kévin Chalard, Marc Mourad, Nacim Benchabane, Racim Benomar et al. · 2021 · Journal of Clinical Medicine
  43. New Approaches in Management of Generalized Scleroderma (Progressive Systemic Sclerosis)
    L. Ananieva, Moscow, Russian Federation · 2021 · Doctor Ru
  44. Addition of antifibrotic therapy to immunosuppression in hypersensitivity pneumonitis: A case series
    Margaret A. Kypreos, Tyonn Barbera, Chad A. Newton, Craig S. Glazer, Traci Nicole Adams · 2021 · Respiratory Medicine Case Reports
  45. Imaging Fibrosis
    Anna Sviridenko, Gianpaolo di Santo, Irene Johanna Virgolini · 2023 · PET Clinics
  46. The interplay between rheumatic diseases and pulmonary health
    Yuliya Fedorchenko, Olena Zimba, Roman Yatsyshyn, Bohdana Doskaliuk, Liubomyr Zaiats, M. V. Fedorchenko · 2024 · Rheumatology International
  47. Pathogenesis of interstitial lung disease in systemic sclerosis
    Nina R. Goldman, Voon Hong Ong, Christopher Paul Denton · 2024 · Rheumatology and Immunology Research
  48. Nintedanib and its combination with immunosuppressives in connective tissue disease-related interstitial lung diseases
    Emre Tekgöz, Seda Çolak, Ezgi Çimen Güneş, Nesrin Öcal, Muhammet Çınar, Sedat Yılmaz · 2024 · Irish Journal of Medical Science (1971 -)
  49. Differences in Tolerability of Antifibrotic Agents Between Connective Tissue Disease-Associated and Non-connective Tissue Disease-Associated Interstitial Lung Disease
    Tomoaki Nakamura, Torahiko Jinta, Atsushi Kitamura, Michiho Tanaka, Clara So, Shosei Ro, Ryosuke Imai, Kohei Okafuji, Yutaka Tomishima, Naoki Nishimura · 2025 · Cureus
  50. Pathophysiological Insights and Clinical Management Strategies for Interstitial Lung Diseases
    Lin Tian, Yun Wang, Wenlong Qi, Bingsen Wang, Xudong Zhang, Mingxue Gong, Xiang Zhang, Tan Wang · 2025 · Biomolecules & Therapeutics
  51. Lung function is associated with minimal EQ-5D changes over time in patients with systemic sclerosis
    Jacopo Ciaffi, Nina Marijn van Leeuwen, Sophie I E Liem, Maarten K. Ninaber, Tom W. J. Huizinga, Jeska Kirsten De Vries-Bouwstra · 2020 · Clinical Rheumatology
  52. Infections and systemic sclerosis: an emerging challenge
    Julian Esteban Barahona Correa, Alejandro De la Hoz, María José López, Javier Garzón, Yannick Allanore, Gerardo Quintana‐López · 2020 · Revista Colombiana de Reumatología (English Edition)
  53. Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysis
    Tim Th. A. Bender, Judith Leyens, Julia Sellin, Dmitrij Kravchenko, Rupert Conrad, Martin Mücke, Matthias F. Seidel · 2020 · Orphanet Journal of Rare Diseases
  54. Ameliorating Fibrosis in Murine and Human Tissues with END55, an Endostatin-Derived Fusion Protein Made in Plants
    Logan Mlakar, Sara M. Garrett, Tomoya Watanabe, Matthew Sanderson, Tetsuya Nishimoto, Jonathan Heywood, Kristi L. Helke, Joseph M. Pilewski, Erica L. Herzog, Carol A. Feghali‐Bostwick · 2022 · Biomedicines
  55. Description of a single centre cohort of patients with systemic sclerosis from the University Hospital of Buenos Aires and factors associated with lung function deterioration. A retrospective study
    Juan Ignacio Enghelmayer, María José López Meiller, Eva Ailín Vallejos, Federico Felder, María Milena Pertuz Rebolledo, Tamara Arias, Cora Gabriela Legarreta, Silvana Acuña, Sebastián Leiva, Vanesa Barrios et al. · 2023 · Reumatología Clínica
  56. Interstitial lung disease—From pulmonary perspective to pathogenesis, multidisciplinary approach and treatment
    Ching‐Yi Lee · 2023 · International Journal of Rheumatic Diseases
  57. Prognosis of patients with systemic sclerosis-related interstitial lung disease on the lung transplant waiting list: a retrospective study
    Yoichi Nakayama, Ran Nakashima, Tomohiro Handa, Akihiro Ohsumi, Yoshito Yamada, Daisuke Nakajima, Yojiro Yutaka, Satona Tanaka, Satoshi Hamada, Kohei Ikezoe et al. · 2023 · Scientific Reports
  58. Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis
    Nicola Farina, Corrado Campochiaro, Alain Lescoat, Giovanni Benanti, Giacomo Davide De Luca, Dinesh Khanna, Lorenzo Dagna, Marco Matucci‐Cerinic · 2023 · Expert Review of Clinical Immunology
  59. Current and emerging treatment options for lung cancer in patients with pre-existing connective tissue disease
    Weihua Shao, Qian Zhou, Xiaokui Tang · 2020 · Pulmonary Pharmacology & Therapeutics
  60. Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies
    Bénédict Fallet, Ulrich Andreas Walker · 2020 · Expert Review of Clinical Pharmacology
  61. Interstitial Pneumonia Secondary to Hermansky-Pudlak Syndrome Type 4 Treated with Different Antifibrotic Agents
    Junko Itano, Yasushi Tanimoto, Goro Kimura, Noboru Hamada, Hisaaki Tanaka, Shinsuke Ninomiya, Kenjiro Kosaki, Nobuaki Miyahara, Yoshinobu Maeda, Katsuyuki Kiura · 2020 · Internal Medicine
  62. Current therapy of interstitial pneumonia associated with systemic scleroderma
    L. Ananieva · 2020 · Rheumatology Science and Practice
  63. Successful treatment of severe interstitial pneumonia by removal of circulating autoantibodies: a case series
    Philipp Eller, Holger Flick, Gernot Schilcher, Florentine Moazedi‐Fürst, Kathrin Eller, Emina Talakić, Josef Hermann, Yannick Allanore, Horst Olschewski · 2021 · BMC Pulmonary Medicine
  64. The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease
    Lutz Wollin, Thuong Trinh‐Minh, Yun Zhang, Jörg H. W. Distler · 2021 · Clinical and Experimental Rheumatology
  65. Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis
    Paul Gressenberger, Philipp Jud, Gábor Kovács, Sonja Kreuzer, H. P. Brezinsek, Katharina Gütl, Viktoria Muster, Ewald Kolesnik, Albrecht G. Schmidt, Balazs Odler et al. · 2021 · Journal of Personalized Medicine
  66. Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database
    Takashi Funatogawa, Yusuke Narita, Aya Tamura, Kazuma Mii, Yasuo Sugitani, Tomoaki Uchida · 2021 · Modern Rheumatology
  67. Systemic Sclerosis
    Michael Hughes, Yannick Allanore, Christopher Paul Denton, Marco Matucci‐Cerinic · 2020 · EMJ Rheumatology
  68. Factors associated with interstitial lung disease and the progressive fibrosing phenotype in rheumatoid arthritis–related interstitial lung disease
    Sahajal Dhooria, Vikram Babu, Varun Dhir, Inderpaul Singh Sehgal, Kuruswamy Thurai Prasad, Valliappan Muthu, Amanjit Bal, Uma Debi, Mandeep Kumar Garg, Ritesh Agarwal et al. · 2022 · Medical Journal Armed Forces India
  69. Current best clinical practices for monitoring of interstitial lung disease
    Elisabeth M. Bendstrup, Sissel Brix Kronborg-White, Janne Møller, Thomas Skovhus Prior · 2022 · Expert Review of Respiratory Medicine
  70. The world is not enough – the value of increasing registry data in idiopathic pulmonary fibrosis
    Catharina C. Moor, Michael Kreuter, Fabrizio Luppi, Wim A Wuyts · 2020 · Respiratory Research
  71. The challenge of diagnosing interstitial lung disease by HRCT: state of the art and future perspectives
    Gaetano Rea, Marialuisa Bocchino · 2021 · Jornal Brasileiro de Pneumologia
  72. Combining rituximab with mycophenolate for the treatment of interstitial lung disease
    Elizabeth R. Volkmann · 2023 · European Respiratory Journal
  73. Enrichment Strategies for Systemic Sclerosis–Interstitial Lung Disease Trials
    Elizabeth R. Volkmann, Donald P. Tashkin · 2024 · American Journal of Respiratory and Critical Care Medicine
  74. Chronic Respiratory Disease: COPD, IPF
    Raffaele Antonelli Incalzi, Filippo Luca Fimognari · 2023 · Practical issues in geriatrics
  75. Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease
    Fabio Perrotta, Stefano Sanduzzi Zamparelli, Vito D’Agnano, Antonia Montella, Ramona Fomez, Raffaella Pagliaro, Angela Schiattarella, Mario Cazzola, Andrea Bianco, Domenica Francesca Mariniello · 2024 · Biomedicines
  76. Innovations in Childhood Interstitial and Diffuse Lung Disease
    Alicia M. H. Casey, Elizabeth K. Fiorino, Jennifer A. Wambach · 2024 · Clinics in Chest Medicine
  77. Treatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results
    Sindhu R. Johnson, Elana J. Bernstein · 2024 · Current Opinion in Rheumatology
  78. Long-term retention rate, adverse event temporal patterns and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life
    Enrico De Lorenzis, Gerlando Natalello, Greta Pellegrino, Lucrezia Verardi, Veronica Batani, Gemma Lepri, Stefano Stano, Giuseppe Armentano, Marco de Pinto, Francesca Motta et al. · 2024 · Rheumatology
  79. Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts
    Hui Fang Huang, Qian Wang, Zuojun Xu · 2024 · Therapeutic Advances in Respiratory Disease
  80. Antifibrotic therapeutic strategies in systemic sclerosis: Critical role of the Wnt/β-catenin and TGF-β signal transduction pathways as potential targets
    Leyla Bagheri, Mohammad Javanbakht, Sheida Malekian, Bahareh Heshmat Ghahderijani, Sadra Taghipour, Fatemeh Davari Tanha, Mohammad Hossein Ranjkesh, Luca Cegolon, Shi Guang Zhao · 2025 · European Journal of Pharmacology
  81. Advances and future outlook in clinical trials for treating systemic sclerosis-interstitial lung disease
    Marzieh Jamali, Rocio Bautista Sanchez, Prachi Pragya Agarwal, Dinesh Khanna · 2025 · Expert Review of Respiratory Medicine
  82. Patient characteristics and pharmacologic treatment patterns in antifibrotic-treated patients with fibrosing interstitial lung diseases: real-world results from a claims database
    Yasuhiro Kondoh, Tomohiro Ito, Hana Kimura, Haikun Bao, Masataka Kuwana · 2025 · BMC Pulmonary Medicine
  83. Predictors of Persistent Disease Activity and Damage in Systemic Sclerosis
    Beatrice Moccaldi, Marco Binda, Salvatore Prete, Andréa Martini, Anna Cuberli, Maria Favarò, Andrea Doria, Elisabetta Zanatta · 2025 · JCR Journal of Clinical Rheumatology
  84. Diagnostics, Efficacy, and Safety of Immunomodulatory and Anti-Fibrotic Treatment for Interstitial Lung Disease Associated with Systemic Scleroderma (SSc-ILD)
    Dawid Piecuch, Edyta Hańczyk, Katarzyna Zemsta, Michał Zwoliński, Szymon Kopciał, Joanna Jońska‐Gmyrek · 2025 · Diagnostics
  85. Pathophysiological Insights and Clinical Management Strategies for Interstitial Lung Diseases
    Lin Tian, Yun Wang, Wenlong Qi, Bingsen Wang, Xudong Zhang, Min Gong, Xiang Zhang, Tan Wang · 2025 · Biomolecules & Therapeutics
  86. Circulating biomarkers in subjects with progressive pulmonary fibrosis: data from the INBUILD trial
    Toby M. Maher, Gisli R. Jenkins, Francesco Bonella, Shervin Assassi, Claudia Diefenbach, Carina Ittrich, Klaus B. Rohr, Martin Kolb · 2025 · ERJ Open Research
  87. Circulating monocytes from systemic sclerosis patients with progressive interstitial lung disease preferentially express M2 phenotype markers: in vitro and ex vivo study
    Vanessa M. Smith, Stefano Soldano, Rosanna Campitiello, Paola Montagna, A. Cere, Elvis Hysa, Tamara Vojinovic, Carmen Pizzorni, Sabrina Paolino, Alberto Sulli et al. · 2025 · RMD Open
  88. Interstitial pneumonia with autoimmune features: A literature review
    Apostolos Perelas, Darryn L. Winter, Jeffrey J. Swigris, Mary E. Strek, Kristin B. Highland · 2026 · Respiratory Medicine
  89. Exploratory evaluation of early 68Ga-FAPI-46 PET/CT volume-based parameters in systemic sclerosis-associated interstitial lung disease
    Sarah Beishan Tai, Wei Ming Chua, Cherie Wei Qi Ng, Maria Noviani, Wei Ping Tham, Seyed Ehsan Saffari, Winnie Wing Chuen Lam, David Chee Eng Ng, Shoen Choon Seng Low, Wanying Xie et al. · 2026 · European Journal of Nuclear Medicine and Molecular Imaging
  90. Management and support of patients with fibrosing interstitial lung diseases
    Tyonn Barbera, Lesley Davila, Nina M. Patel · 2021 · The Nurse Practitioner
  91. Serum and bronchoalveolar lavage fluid levels of soluble B7H3 in patients with interstitial lung diseases
    Taku Nakashima, Keitaro Omori, Masashi Namba, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Yasushi Horimasu, Takeshi Masuda, Shintaro Miyamoto, Hiroshi Iwamoto, Kazunori Fujitaka et al. · 2023 · Respiratory Medicine
  92. Interstitial lung disease related to occupational hard metal exposure: two case reports
    I-Fan Lin, Hsiao‐Chin Shen, Shiou‐Fu Lin, Ho-Chuen Chang, Tzu-Tao Chen · 2023 · Journal of Medical Case Reports
  93. Skin Gene Expression Profiles in Systemic Sclerosis: From Clinical Stratification to Precision Medicine
    Devis Benfaremo, Silvia Agarbati, Matteo Mozzicafreddo, Chiara Paolini, Silvia Svegliati, Gianluca Moroncini · 2023 · International Journal of Molecular Sciences
  94. Interstitial lung disease in autoimmune diseases
    Vivek Nagaraja, Isabel C. Mira-Avendano, ALEJANDRO DIAZ ARUMIR VERGARA, Michael B. Gotway, Ana Zamora · 2024 · Revista Colombiana de Reumatología
  95. Dysregulation of TNF‐induced protein 3 and CCAAT/enhancer‐binding protein β in alveolar macrophages: Implications for systemic sclerosis‐associated interstitial lung disease
    Hua Xiao, Rui Hongbing, Xue Juan, Liu Jizan, Yang Beibei · 2024 · International Journal of Rheumatic Diseases
  96. Assessing the quality of forced vital capacity measurement in patients with systemic sclerosis
    G. Sandal Uzun, Alper Sarı, Oğuz Karcıoğlu, Elif Naz Sancar, Erdinç Ünaldı, Büşra Fırlatan, Gözde Sevgi Bayram, Levent Kılıç, Ali Akdoğan · 2024 · Seminars in Arthritis and Rheumatism
  97. Trajectories of forced vital capacity in patients with systemic sclerosis-associated interstitial lung disease
    Oliver Distler, Madelon C Vonk, Arata Azuma, Maureen Davidica Mayes, Dinesh Khanna, Kristin B. Highland, Gerrit Toenges, Margarida Alves, Yannick Allanore · 2025 · Arthritis Research & Therapy
  98. Pragmatic Comparative Effectiveness Trials in Rheumatoid Arthritis-Associated Interstitial Lung Disease
    Angela Kaczorowski-Worthley, Dinesh Pal Mudaranthakam, Janell Reichuber, CHRISTOPHER STREILER, S.M. Pandya, R. Boente, Susan K. Mathai, Ayodeji Adegunsoye, Jeffrey J. Swigris, Elizabeth R. Volkmann et al. · 2025 · CHEST Pulmonary
  99. Novel Imaging Strategies in Systemic Sclerosis
    Molly Wolf, Sydney B. Montesi · 2020 · Current Rheumatology Reports
  100. Use of biologics for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database
    Yusuke Narita, Takashi Funatogawa, Kazuma Mii, Hiroki Adachi, Aya Tamura, Shinji Yamakido · 2022 · Modern Rheumatology